Get the Stockscreener App
33.32
1.34%
0.44
After Hours:
33.48
0.16
+0.48%
Ionis Pharmaceuticals Inc stock is traded at $33.32, with a volume of 2.10M.
It is up +1.34% in the last 24 hours and down -4.58% over the past month.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.
See More
Previous Close:
$32.88
Open:
$33.08
24h Volume:
2.10M
Relative Volume:
1.47
Market Cap:
$5.26B
Revenue:
$803.07M
Net Income/Loss:
$-358.81M
P/E Ratio:
-13.66
EPS:
-2.44
Net Cash Flow:
$-374.21M
1W Performance:
-3.31%
1M Performance:
-4.58%
6M Performance:
-33.07%
1Y Performance:
-35.80%
1-Day Range:
$31.82
$33.36
1-Week Range:
$31.82
$35.31
52-Week Range:
$31.40
$52.49
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
Name
Ionis Pharmaceuticals Inc
Sector
Industry
Phone
(760) 931-9200
Address
2855 GAZELLE COURT, CARLSBAD, CA
Compare IONS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IONS
Ionis Pharmaceuticals Inc
|
33.32 | 5.26B | 803.07M | -358.81M | -374.21M | -2.44 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 112.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 75.06B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.45B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.75B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 28.98B | 3.30B | -501.07M | 1.03B | -2.1146 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-02-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jul-24-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jul-16-24 | Resumed | Jefferies | Buy |
| Jun-14-24 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Apr-10-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-02-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-23-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Sep-29-23 | Initiated | Raymond James | Strong Buy |
| Jul-31-23 | Upgrade | Citigroup | Neutral → Buy |
| Jun-07-23 | Resumed | Piper Sandler | Overweight |
| May-04-23 | Upgrade | Citigroup | Sell → Neutral |
| Mar-21-23 | Initiated | Bernstein | Underperform |
| Dec-21-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-09-22 | Resumed | Morgan Stanley | Overweight |
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
| Mar-31-22 | Resumed | Piper Sandler | Overweight |
| Mar-01-22 | Initiated | Citigroup | Sell |
| Mar-01-22 | Initiated | Guggenheim | Buy |
| Feb-01-22 | Downgrade | BofA Securities | Buy → Underperform |
| Dec-14-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| May-07-21 | Upgrade | UBS | Sell → Neutral |
| Mar-01-21 | Upgrade | Barclays | Underweight → Equal Weight |
| Dec-16-20 | Initiated | UBS | Sell |
| Dec-15-20 | Upgrade | Cowen | Market Perform → Outperform |
| Sep-14-20 | Resumed | JP Morgan | Neutral |
| Sep-02-20 | Initiated | The Benchmark Company | Hold |
| Jun-01-20 | Resumed | Oppenheimer | Outperform |
| May-13-20 | Initiated | RBC Capital Mkts | Outperform |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Dec-13-19 | Initiated | Oppenheimer | Outperform |
| Nov-13-19 | Initiated | BofA/Merrill | Buy |
| Nov-07-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Sep-10-19 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Aug-08-18 | Reiterated | Stifel | Hold |
| Aug-07-18 | Reiterated | Stifel | Hold |
| May-08-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-06-17 | Resumed | Goldman | Sell |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Aug-09-17 | Reiterated | Stifel | Hold |
| Mar-10-17 | Downgrade | Goldman | Neutral → Sell |
| Dec-28-16 | Reiterated | BMO Capital Markets | Outperform |
| Dec-27-16 | Reiterated | Leerink Partners | Mkt Perform |
View All
Ionis Pharmaceuticals Inc Stock (IONS) Latest News
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Bought by SG Americas Securities LLC - MarketBeat
Familial Chylomicronemia Syndrome FDA Approvals, Clinical - openPR
September 19th Options Now Available For Ionis Pharmaceuticals - Nasdaq
Ionis Pharmaceuticals (NASDAQ:IONS) Shares Up 7%Time to Buy? - MarketBeat
FDA & EMA Accept Biogen's Filings for Higher Dose SMA Drug - Yahoo Finance
What is Leerink Partnrs’ Forecast for IONS FY2024 Earnings? - Defense World
Spinocerebellar Ataxias Pipeline 2024: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Biogen Inc, BioXcel Corp, Celavie Biosciences, Ionis Pharma - Barchart
70+ Key Companies Advancing in Dry Age-Related Macular Degeneration Clinical Trial Therapeutic Space | DelveInsight - Yahoo Finance
Ionis stock rises on FDA, EMA nod for SMA drug dose increase - MSN
William Blair Brokers Increase Earnings Estimates for IONS - MarketBeat
Biogen/ Ionis Spinraza being reviewed for higher dose (BIIB) - Seeking Alpha
Leerink Partnrs Has Negative Outlook of IONS FY2024 Earnings - MarketBeat
Ionis Pharmaceuticals Insiders Sold US$3.2m Of Shares Suggesting Hesitancy - Simply Wall St
Transthyretin Amyloid Cardiomyopathy Treatment Market - openPR
Assenagon Asset Management S.A. Raises Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - MarketBeat
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Position Boosted by Assenagon Asset Management S.A. - Defense World
Ionis Pharmaceuticals EVP sells $241,628 in stock - MSN
Ionis Pharmaceuticals EVP Brian Birchler sells $176,580 in stock - MSN
Ionis Pharmaceuticals exec sells $144,861 in stock - MSN
Ionis Pharmaceuticals EVP Eric Swayze sells $235,678 in stock - MSN
Ionis Pharmaceuticals CEO Brett Monia sells $1.09 million in stock - MSN
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Eric Swayze Sells 7,154 Shares - MarketBeat
Brett P. Monia Sells 33,445 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Stock - MarketBeat
Ionis Pharmaceuticals CFO sells stock worth $290,989 - MSN
Ionis Pharmaceuticals exec sells $144,861 in stock By Investing.com - Investing.com Australia
Ionis Pharmaceuticals EVP sells $232,407 in stock By Investing.com - Investing.com Australia
Ionis Pharmaceuticals EVP sells $213,889 in stock - MSN
Ionis Pharmaceuticals EVP sells $232,407 in stock - MSN
Bennett C. Frank of Ionis Pharmaceuticals sells $222,113 in stock - MSN
Ionis Pharmaceuticals EVP Brian Birchler sells $176,580 in stock By Investing.com - Investing.com Australia
Ionis Pharmaceuticals EVP Eric Swayze sells $235,678 in stock By Investing.com - Investing.com South Africa
Ionis Pharmaceuticals CFO sells stock worth $290,989 By Investing.com - Investing.com South Africa
Ionis Pharmaceuticals EVP sells $241,628 in stock By Investing.com - Investing.com Canada
EVP, Chf Clinical Develop Ofcr Schneider Eugene converted options into 17,372 shares and sold $213,889 worth of shares (6,523 units at $32.79), increasing direct ownership by 23% to 58,508 units (SEC Form 4) - Quantisnow
Director Yang Michael J. converted options into 1,931 shares (SEC Form 4) - Quantisnow
EVP Research Swayze Eric converted options into 19,160 shares and sold $235,678 worth of shares (7,176 units at $32.84), increasing direct ownership by 35% to 45,670 units (SEC Form 4) - Quantisnow
Ionis Pharmaceuticals (NASDAQ:IONS) Hits New 12-Month LowTime to Sell? - MarketBeat
Why Ionis Pharmaceuticals (IONS) Is the Biotech Stock with Biggest Upside Potential - Insider Monkey
Familial Lipoprotein Lipase Deficiency Market to Continue - openPR
Retinitis Pigmentosa Pipeline Assessment 2024: Therapies, Clinical Trials, and Key Companies involved by DelveInsight | Biogen, Neurotech, Ionis Pharma, Nacuity Pharma, Allegro Ophthalmics, ID Pharma - Barchart
Ionis Pharmaceuticals Inc Stock (IONS) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.49%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):